Samsung Epise Holdings has established a research and development (R&D) hub in Beijing to accelerate the development of antibody-drug conjugate (ADC) based new drugs. This center marks the company's first overseas R&D facility and will operate as a specialized organization focused on enhancing ADC technology and drug development capabilities.
On July 1, Samsung Epise Holdings announced that it officially commenced R&D activities following the opening ceremony of the 'Samsung Bioepis China R&D Center' held in Changping District, Beijing, on June 30.
Earlier in May, Samsung Epise Holdings established a wholly-owned subsidiary, 'Samsung Biologics China Co., Ltd.,' in Changping District for biopharmaceutical research and development.
Founded in November 2022, Samsung Epise Holdings is a bio investment holding company that has focused on building a global R&D foundation to expand its new business ventures.
Changping District, where the center is located, is recognized as a bio cluster housing the Zhongguancun Life Science Park and is in proximity to major universities such as Peking University and Tsinghua University, making it a competitive area in terms of talent and research infrastructure.
Kim Kyung-ah, President of Samsung Epise Holdings, stated, "The opening of the China R&D Center marks the first step in building a global R&D network. We will continue to expand our new business through collaboration with the Chinese bio ecosystem, including the discovery of innovative drug candidates."
Meanwhile, analysts predict that Samsung Epise Holdings' key subsidiary, Samsung Bioepis, will continue to increase its market share in the U.S. and European markets through a stable biosimilar portfolio and is expected to enter a high-growth phase over the next three to five years with new product launches.
Seo Geun-hee, a researcher at Samsung Securities, remarked, "Samsung Epise Holdings is likely to be reevaluated as a global bio platform holding company centered around Samsung Bioepis, rather than just a biosimilar company."
On July 1, Samsung Epise Holdings announced that it officially commenced R&D activities following the opening ceremony of the 'Samsung Bioepis China R&D Center' held in Changping District, Beijing, on June 30.
Earlier in May, Samsung Epise Holdings established a wholly-owned subsidiary, 'Samsung Biologics China Co., Ltd.,' in Changping District for biopharmaceutical research and development.
Founded in November 2022, Samsung Epise Holdings is a bio investment holding company that has focused on building a global R&D foundation to expand its new business ventures.
Changping District, where the center is located, is recognized as a bio cluster housing the Zhongguancun Life Science Park and is in proximity to major universities such as Peking University and Tsinghua University, making it a competitive area in terms of talent and research infrastructure.
Kim Kyung-ah, President of Samsung Epise Holdings, stated, "The opening of the China R&D Center marks the first step in building a global R&D network. We will continue to expand our new business through collaboration with the Chinese bio ecosystem, including the discovery of innovative drug candidates."
Meanwhile, analysts predict that Samsung Epise Holdings' key subsidiary, Samsung Bioepis, will continue to increase its market share in the U.S. and European markets through a stable biosimilar portfolio and is expected to enter a high-growth phase over the next three to five years with new product launches.
Seo Geun-hee, a researcher at Samsung Securities, remarked, "Samsung Epise Holdings is likely to be reevaluated as a global bio platform holding company centered around Samsung Bioepis, rather than just a biosimilar company."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.